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Abstract 
BACKGROUND: In patients with breast cancer, HER2 gene expression is of a great importance in reacting to 
Herceptin treatment. To evaluate this event, immunohistochemistry (IHC) has been done routinely on the basis of 
scoring it and so the patients were divided into 4 groups. Lately, as there have been disagreements about how to 
treat score 2 patients, chromogenic in situ hybridization (CISH) and florescence in situ hybridization (FISH) are 
introduced. Since CISH method is more convenient than FISH for gene amplification study, FISH has been 
substituted by CISH.  
AIM: The current study is conducted in order to investigate whether using CISH is a better method comparison to 
IHC method for determines HER2 expression in patients with breast cancer in. 
METHODS: In this cross-sectional descriptive analytical study, information of 44 female patients with invasive 
ductal breast cancer were gathered from Imam Reza and Omid Hospital in Mashhad. IHC staining was done for 
all patients in order to determine the level of HER2 expression, and after scoring them into 4 groups of 0, +1, +2 
and +3, CISH staining was carried out for all 4 groups. At the end, results from both methods were statistically 
evaluated using SPSS software V.22.0. 
RESULTS: The average age of patients was 50.2 with the standard deviation of 10.96. Using IHC method was 
observed that 2.6% (1 patient), 26.3% (10 patients), 65.8% (25 patients) and 5.3% (2 patients) percentage of 
patients had scores of 0, +1, +2 and +3. On the other hand, CISH method showed 36 patients (90%) with no 
amplifications and 4 (10%) with sever amplifications. In a comparative study using Fisher's exact test (p = 0.000), 
we found a significant relation between IHC method and CISH method indicating that all patients showing severe 
amplifications in CISH method, owned scores of +2 and +3 in IHC method. 
CONCLUSION: According to the present study and comparing the results with similar previous studies, it can be 
concluded that CISH method works highly effective in determining HER2 expression level in patients with breast 
cancer. This method is also able to determine the status of patients with score +2 in IHC for their treatment with 
herceptin. 
 
 
 
 
 
 
 
 
Introduction 
 
Breast cancer is the second death-causing 
cancer amongst women worldwide and is also the 
main death cause of women between 20 and 40 [1]. 
Breast cancer is the most prevalent malignancy in 
Middle Eastern women [2]. Previous review studies on 
breast cancer conducted in Iran, haves also shown an 
occurrence of about 17.2-22 cases in 100,000 
individuals [3]. About 72% of patients in Iran had a 
tumor bigger than 2 centimeters at a time of diagnosis 
diagnosed [3].  
In order to treat breast cancer patients who 
need to systemic or complementary treatment, after 
local treatment, there are three remedial processes 
including hormonal therapy, chemotherapy and 
human monoclonal antibody therapy like anti 
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Herceptin. Monoclonal antibody therapy which in this 
particular cases the human monoclonal antibody 
would be anti-herceptin. Choosing between different 
treatment processes depends on how the patient 
reacts to the hormonal therapy and their level of 
HER2 expression [4]. HER2 is an oncogene coding a 
185-kDa transmembrane glycoprotein expressing 
intracellular tyrosine kinase activities. HER2 receptor 
belongs to epidermal growth factor receptors (EGFR) 
which effects on activation of cascades cellular 
mechanisms leading to growth and development [5, 
6]. Increased gene expression of HER2 is observed in 
18 to 20 percent of breast cancer cases [5] [7] [8]. 
Patients with high levels of HER2 expression respond 
better to medications like Herceptin. Also, the level of 
HER2 can expose patient’s sensitivity or resistance to 
chemotropic drugs [9]. Furthermore, recent studies 
have shown that patients with HER2 expression are 
resistant to hormonal therapies [10]. 
Determining HER2 level is a necessity for 
choosing the best treatment for breast cancer patients 
and is done through three methods: IHC, FISH, CISH. 
In IHC method, patients are categorized into 4 scores, 
which due to mismatched results between different 
labs and therapy of choice disagreements, it is 
necessary to recheck HER2 level with either CISH or 
FISH. Since FISH method also has some drawbacks 
such as limitations on keeping results, high costs and 
the need of a florescence microscope, CISH is 
preferred as it offers a much higher accuracy and 
sensitivity level [7] [11] [12] [13] [14] [15]. 
In keeping with previous studies in this area, 
we decided to compare the evaluating competence of 
CISH and IHC methods in determining HER2 level in 
breast cancer patients. 
 
 
Material and Methods 
 
Female patients with invasive ductal breast 
cancer whose tissue samples and paraffin blocks 
were kept in Imam Reza (pbuh) and Omid hospital at 
Mashhad were included in this sectional descriptive 
analytical study. Cases with not enough tissue 
samples for IHC or CISH were excluded from the 
study, as well as those with in situ carcinoma or other 
form of breast cancer. 
IHC staining was done for all the patients to 
determine HER2 expression level. New sections were 
prepared from each block to be stained. Blocks were 
deparaffinized at first and then was added Citrate 
buffer in 94°C for 30 min. After that, one overnight 
incubation with monoclonal antibody (HER2-pY 1248, 
Dako Denmark A/S) was done at 37°C. 
Diaminobenzidine was used as chromogen in a 
standard process of Avidin-Biotin- peroxidase staining 
in IHC method. After slides preparation, each of them 
was stained individually to determine the HER2 level. 
After that, HER2 staining, results were 
reported in 4 different groups of 0, +1, +2 and +3. 
Score 0 (negative result is assigned to those cases 
showing no detectable stained cells or stained cells 
are observed in less than 10% of tumor cells). Score 
+1 is assigned to colorfulness with less than 10% 
weakly stained tumor cells membrane, score +2 
includes cases with weakly to partial stained in more 
than 10% of tumor cells membrane, and +3 is for 
cases with more than 30% complete and strongly 
stained tumor cells membrane (Figure 1) [16].  
 
Figure 1: Microscopic pictures of immunohistochemistry samples in 
order to investigate HER2 gene in breast cancer; a) Score 0-1; b) 
Score +2; c) Score +3 
 
After scoring the samples using IHC 
(according to the level of membrane staining intensity 
and the percentage of stained cells) samples were 
divided into 4 groups of 0, +1, +2 and +3 and then 
according to the provided instruction for ZytoDot Kit 
(ZytoDot 2C, Zytovision, Germany) staining was 
conducted for all samples. This technique was carried 
out on 4-5 µm sections of paraffinized tissue blocks. 
In site hybridization technique (ISH) refers to 
an operation which a single-stranded DNA or RNA 
attach as a probe with a portion of the single-stranded 
DNA of the cell as a target. In-situ hybridization can 
be done in a liquid medium or in a solid medium. And 
the labeled material in probes can be chromogenic 
enzymes or fluorescent compounds. If hybridization is 
performed locally in the sample cells, hybridization is 
called in situ or Hybridization (ISH). So, the CISH 
method is a hybridization technique in the main site 
(ISH). In CISH, the generated signal is a kind of color 
that appears under the Bright field light microscope. 
Generally, tissues 4–5 μm thick were 
mounted on Histogrip-treated microscope slides then 
dried at 37°C, and baked for 2–4 hours at 60°C. The 
slides were deparaffinized for 15 min three times in 
xylene at room temperature (22–27°C) and washed 
for 2 min three times in 100% ethanol.  
These slides were microwaved in SPOT-Light 
Tissue Heat Pretreatment Buffer for 10 min at 92°C 
and cleaned for 3 min three times in phosphate-
buffered saline (PBS). They were supported with 100 
μl SPOT-Light Tissue Pretreatment Enzyme for 10 
min at 37°C and washed for 3 min three times in PBS 
at room temperature. Then, the slides were 
dehydrated in 70%, 85%, 95%, and 100% ethanol for 
2 min, after that air-dried. Probe (15 μl) had been 
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added to each sample and followed up with a 24 mm 
× 32 mm coverslip, after that the slides were 
denatured at 94°C for 3 min and located in a dark 
humidity box for 16–24 hours at 37°C.After removal of 
the rubber cement and coverslip, the slides were 
soaked in 0.5 × SCC buffer in a Coplin jar for 5 min at 
75°C. Then they were washed for 2 min three times 
by PBS-Tween 20 buffer at RT. After Using ZytoDot 
2C, Zytovision, Germany CISH kit, the slides were 
counterstained with 150 μl of Gill-2 hematoxylin and 
incubated for 3 min. They were then mounted with a 
coverslip (Figure 2).  
 
Figure 2: Chromogenic in situ hybridisation (CISH) of HER-2 
oncogene in breast cancer; A) With normal HER2 copy number 
(1000 X) with no amplification; B) CISH on a breast carcinoma with 
low level HER2 gene amplification (1000 X); C) CISH on a breast 
carcinoma with high level HER2 gene amplification (1000 X) 
 
Results were observed under the light 
microscope with 40x and 100x magnifications by 2 
experienced pathologists, who were not aware of IHC 
results beforehand. Invasive tumor areas were 
recognized and dimensionally analyzed afterwards. 
HER2 signal, indicating a copy of its gene, was 
observed as a detectable green spot and signals of 
chromosome 17 centromere was observed as a red 
spot, where these two were simply distinguishable. In 
a normal diploid nucleus without amplifications, 2 
green spots and 2 red spots with smooth rounded 
edges were seen in each nucleus. Then, 100 cells 
were counted and the ratio of hybridized probe HER2 
genes to signals of chromosome 17 centromere was 
calculated. Necrotic zones, overlapped nuclei and 
nucleus with undetectable signals were omitted. 
Since mitosis can cause extra signals in a few 
percent of non-neoplastic cells; in cases with 
heterogeneity, those areas in tumor which showed 
amplifications, were selected. Samples with the ratio 
of 2.5 or more were considered as having 
amplification and those with the rate less than 2.5 
amplifications. Results were categorized based on 
kit’s instructions: 
1. Less than 5 copies of HER2 gene in ratio 
with 2 signals of control (chromosome 17 centromere) 
in each cell nuclei of 100 counted cells mean there 
has been no amplifications. 
2. Having 5 or more copies of HER2 gene in 
ratio with 2 signals of control (chromosome 17 
centromere), which is sometimes seen as a gene 
cluster in tumor cell nucleus is considered as 
amplification. 
In cases with no amplifications at diploid cells, 
1 to 2 signals and in chromosomal aneuploidy 
situation, 2 to 4 signals were observed in each 
nucleus. 
As an internal control, lymphocytes and 
stromal cells were examined and showed 2 signals 
with smooth rounded edges in each nucleus. 
For quality control part, signals must be clear 
and easily detectable; also it’s necessary to have 
internal control and morphologically healthy cells. 
Damaged nuclei show extra enzyme digestion which 
in turn causes dispersed signals or no signals at all. 
At the end, statistical analysis was carried out 
between so called methods using software as below: 
Data were analyzed using the statistical 
analysis software SPSS vs.22 in order to describe the 
data generally, statistical indexes like, mean, median 
standard deviation and ranges were used. For the 
main data analysis Chi-squared test was used to 
determine the relation between HER2 gene 
amplification and the score each carcinoma sample 
gained in IHC. P < 0.05 was regarded as statistically 
significant. 
 
 
Results 
 
A group of 40 patients with breast cancer 
were included in this study. The average age of the 
participant was 50.2 with the standard deviation of 
10.96. The youngest patient was 26 and the oldest 
was 81 years old. 
Among all patients, 92.6% were married and 
7.4% were single. Tumor grade frequencies for scores 
I, II and III were 2.7%, 86.5% and 10.8% respectively 
(NA is assigned to those with no amplification and 
having amplification in the graph) (Figure 3). 
Furthermore, based on tumor (T) properties, 10%, 
86.7% and 3.3% of patients were classified as T1, T2 
and T3 (Figure 4). 
 
Figure 3: The frequency of grade tumor in samples examined by the 
method CISH 
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Evaluations using IHC method showed that 
respectively 2.6%, 26.3%, 65.8% and 5.3% of patients 
had scores of 0, +1, +2 and +3. In the other evaluation 
carried out by CISH method, 36 (90%) samples had 
not and 4 (10%) had amplification. 
 
Figure 4: The frequency of tumor characteristics (T) in samples 
studied by CISH method 
 
In comparative study between IHC and CISH 
methods, A significant relationship was found between 
the two methods using Fisher’s exact test (p = 0.000) 
all the samples with no amplification in CISH method 
had the, scores of +2 and +3 in IHC. It was also 
recognized that among 25 samples with the score +2 
in IHC, only 2 of them showed signs of amplifications 
in CISH while others were negative for amplification 
(Figure 5). 
 
Figure 5: The frequency of results comparing IHC and CISH 
methods in diagnosis 
 
Also Chi-square test showed a significant 
relation between CISH and tumor (T) properties (p = 
0.009). On the other hand, the T-test didn’t show any 
significant relation between CISH results and patient’s 
age (p = 0.07). 
In addition, when comparing between CISH 
and Tumor Grade, it came to our notice that most of 
the samples with no amplifications were of level II (p = 
0.003). In the other comparison between IHC and 
tumor (T) properties, Kruskal-Walis test showed no 
significant relation between IHC and tumor (T) 
properties (p = 0.991). Also, in comparison between 
IHC and Tumor Grade, Kruskal-Walis test showed no 
significant relation between IHC and Tumor Grade (p 
= 0.993). 
 
 
Discussion 
 
Breast cancer is the second most prevalent 
cancer after skin cancer and is the second fatal 
cancer after lung cancer. It has been established 
through in various previous studies that HER2 gene 
amplification has appeared in 18-20% percent of 
breast cancer patients which in turn increases the 
mortality rate amongst these patients [17]. Since 
positive HER2+ patients demonstrate better 
responses to the treatment with monoclonal Ab 
Herceptin, it would be advantageous to locate HER2 
gene. According to previous studies in determining the 
status of HER2 IHC method is used first. Soon after, 
with CISH having such unique properties, this method 
of staining was chosen to investigate HER2 gene 
amplification [6] [13] [14] [16] [18] [19] [20] [21]. 
Therefore, this study was conducted to 
investigate the quality of diagnosis of CISH and 
compare CISH with IHC in scoring efficacy of 40 
patients with invasive ductal breast cancer. Our 
results demonstrated a relation between CISH and 
IHC in scoring patients. This means that all the 
patients examined in CISH method, also showed high 
amplifications, manifested high amplification for HER2 
gene in IHC method as well (score +2 and score +3). 
So, for these patients, CISH can be used with high 
certainty. 
In other studies conducted in France on 79 
patients with invasive ductal breast cancer and in US 
involving 161 patient with the same problem 
confirmed that results obtained from CISH method for 
determining the level of HER2 gene amplification is 
more than 90% consistent with others method .and on 
the other hand, it can be used as a check test for 
patients with score +2 in IHC method [17] [22]. In a 
study carried out in Spain addressing the same issue, 
the compatibility of positive cases in CISH and IHC 
has been reported to be 72.5% and for negative 
cases, results of these 2 methods were 100% 
compatible. However, they could find no significant 
relationship between CISH, IHC with tumor grade 
which shows the specificity and novelty of this article. 
[23]. It has been clarified in other studies that HER2 
gene expression level is crucial in how patients would 
respond to treatment with Herceptin. So in this study, 
IHC was done routinely and patients were classified 
into 4 scores and since there have been 
disagreements regarding treatment of choice for score 
+2 patients, CISH was used in this study confirmed 
the efficacy of CISH over IHC and showed a 
significant relation between CISH an IHC, meaning 
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that for any sample showing amplification in CISH, 
there would be a score +2 and +3 in IHC (p = 0.000). 
Considering the result from the present study 
and comparing them with previous research on the 
issues it can be concluded that since CISH method is 
a more reliable method, with lower costs and which no 
need for Epi-fluorescent microscope, and since it also 
enables the researcher to simultaneously examine 
morphology and results of hybridization; it can be 
used as a highly effective method for determining 
HER2 expression level in patients with breast cancer. 
However, having some key limitations in this study like 
small sample size and unavailability of patient’s 
detailed information such as the exact number of 
involved auxiliary lymph nodes and expanse of 
metastasis around the hand, it appears that 
conducting similar using a larger sample size can help 
in validating the results obtained from this study.  
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